Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of NASH on 99mTc-Mebrofenin Disposition
NCT02235233Phase 1Completed
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- Apr 2015
- Primary completion
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of Technetium Tc-99m mebrofenin in Nonalcoholic steatohepatitis (NASH) (2 arms), sponsored by University of North Carolina at Chapel Hill. Primary endpoint: Hepatic exposure (AUC0→∞). Started Apr 2015; status: completed.
02
Drugs
Technetium Tc-99m mebrofenin
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT02235233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02235233.